On Tuesday, Cathie Wooden-led Ark Make investments executed a major commerce involving Tempus AI Inc TEM.
The Tempus AI Commerce
Ark Make investments’s determination to promote Tempus AI Inc TEM shares on Tuesday was executed via ARK Genomic Revolution ETF ARKG and ARK Innovation ETF ARKK. ARKG offloaded 6,309 shares, whereas ARKK bought 19,627 shares. With the inventory closing at $81.01, the full worth of the shares bought amounted to roughly $2.1 million.
See Additionally: UnitedHealth Group Uncommon Choices Exercise For September 09
This transfer comes within the wake of Tempus AI’s latest acquisition of Paige, an organization specializing in digital pathology, which had beforehand pushed the inventory greater.
In the meantime, HC Wainwright reduce its Tempus AI goal to $90 however stored a Purchase, whereas Morgan Stanley and BTIG maintained Chubby and Purchase rankings with $68 and $85 targets, respectively, in keeping with knowledge from Benzinga Professional.
Different Key Trades
- Prime Drugs Inc (PRME): Ark Make investments’s ARKG fund bought 157,413 shares.
- Twist Bioscience Corp (TWST): The ARKG fund purchased 5,405 shares, whereas the ARKK fund acquired 42,327 shares.
Benzinga’s Edge Inventory Rankings present that Tempus AI inventory checks out on Brief, Medium and Lengthy Value Traits. Right here is how the inventory ranks on different metrics.
Learn Subsequent:
Photograph: ChrisStock82 / Shutterstock
This story was generated utilizing Benzinga Neuro and edited by Shivdeep Dhaliwal
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.